- Adverse reactions include hypersensitivity (1%), itching (3%), and injection-site reactions (4%)1,a
- Formation of inhibitors and thrombotic complications have been associated with FIX treatment. Monitor patients for the development of inhibitors and signs of thrombosis1
SAFETY PROFILE
The safety of Rebinyn® has been studied in clinical trials, with 0 inhibitors and thrombotic events confirmed in 115 previously treated males over 8801 exposure days.1,2,a
Results from studies with previously treated patients:
and thrombotic events1,2,a
aIdentified in 115 previously treated patients who were treated with Rebinyn® in clinical studies. A previously treated patient was defined as a subject with a history of at least 150 exposure days to other FIX products (adolescent/adult subjects) or 50 exposure days to other FIX products (pediatric subjects) and no history of inhibitors. There were a total of 8801 exposure days, equivalent to 170 patient-years. A total of 40 patients (35%) were treated for more than 2 years.
SAFETY PROFILE
The safety of Rebinyn® has been studied in clinical trials, with 0 inhibitors and thrombotic events confirmed in 115 previously treated males over 8801 exposure days.1,2,a
Results from studies with previously treated patients:
and thrombotic events1,2,a
- Adverse reactions include hypersensitivity (1%), itching (3%), and injection-site reactions (4%)1,a
- Formation of inhibitors and thrombotic complications have been associated with FIX treatment. Monitor patients for the development of inhibitors and signs of thrombosis1
aIdentified in 115 previously treated patients who were treated with Rebinyn® in clinical studies. A previously treated patient was defined as a subject with a history of at least 150 exposure days to other FIX products (adolescent/adult subjects) or 50 exposure days to other FIX products (pediatric subjects) and no history of inhibitors. There were a total of 8801 exposure days, equivalent to 170 patient-years. A total of 40 patients (35%) were treated for more than 2 years.
MANUFACTURED TO HELP ENSURE SAFETY AND PURITY
Rebinyn® is a recombinant factor IX treatment made without human blood, plasma, or proteins. Recombinant factor IX products are recommended as a first-line therapy for patients with hemophilia B.3
What are the latest recommendations?
The National Hemophilia Foundation’s Medical and Scientific Advisory Council (MASAC) recommends recombinant factor IX products as a first-line therapy for patients with hemophilia B.3
Animals administered repeat doses of Rebinyn® showed accumulation of PEG in the choroid plexus. The potential clinical implications of these animal findings are unknown.
REBINYN® TRIAL PROGRAM
Considering Rebinyn® for your patients with hemophilia B? Get a 1-month trial prescription for qualifying patients.b
To learn more about our trial prescription program, please call 1-844-NOVO-SEC (1-844-668-6732) to speak with a NovoSecure™ Specialist.
bPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
REBINYN® TRIAL PROGRAM
Considering Rebinyn® for your patients with hemophilia B? Get a 1-month trial prescription for qualifying patients.b
To learn more about our trial prescription program, please call 1-844-NOVO-SEC (1-844-668-6732) to speak with a NovoSecure™ Specialist.
bPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
CONNECT WITH US
Novo Nordisk representatives are here to help. Enter your zip code to find a Novo Nordisk representative.
EXTENDING HALF-LIFE
Rebinyn® stays in the body longer through PEGylation technology.4
CONNECT WITH US
Novo Nordisk representatives are here to help. Enter your zip code to find a Novo Nordisk representative.
EXTENDING HALF-LIFE
Rebinyn® stays in the body longer through PEGylation technology.4
REGISTER TO GET THE LATEST UPDATES ON REBINYN®
